https://www.selleckchem.com/products/OSI-906.html
Especially given the prospect, that the health care system faces a greater load of patients with diabetes and other immunodeficiencies in the future.Background Recent cost-utility analysis (CUA) models for onasemnogene abeparvovec (Zolgensma®, formerly AVXS-101) in spinal muscular atrophy type 1 (SMA1) differ on key assumptions and results. Objective To compare the manufacturer's proprietary CUA model to the model published by the Institute for Clinical and Economic Review (ICER), and to update the manufacturer's model with long-term fo